The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients
Background: Platelet activation and aggregation plays an essential role in the for-mation of coronary artery thrombosis. Nowadays, the Clopidogrel is administered oral-ly as an inhibitor of platelet aggregation. Due to the high price of the original brand of Clopidogrel (Plavix), an Iranian brand of...
Main Authors: | Behzad Imani, Reza Safi-Ariyan, Babak Manaafi, Arezo Karampourian, Karim Ghazikhanlou Sani |
---|---|
Format: | Article |
Language: | fas |
Published: |
Tehran University of Medical Sciences
2014-07-01
|
Series: | Tehran University Medical Journal |
Subjects: | |
Online Access: | http://tumj.tums.ac.ir/browse.php?a_code=A-10-25-5216&slc_lang=en&sid=1 |
Similar Items
-
ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL
by: K. Yu. Lukianets, et al.
Published: (2020-10-01) -
Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV
by: Emanuela Marcantoni, PhD, et al.
Published: (2022-11-01) -
Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
by: Jianyu Qu, et al.
Published: (2021-06-01) -
Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial
by: Rafiq Sulman, et al.
Published: (2012-04-01) -
ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY
by: V. V. Yakusevich, et al.
Published: (2014-07-01)